<DOC>
	<DOCNO>NCT02380976</DOCNO>
	<brief_summary>A randomized , open-label , single-dose , crossover Phase I Study investigate relative bioavailability DW340 DW330SR + DW1030 co-administration healthy male volunteer .</brief_summary>
	<brief_title>Phase 1 Clinical Trial DW340 DW330SR + DW1030 Co-administration Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Age screen visit 20 healthy men age 40 year less Screening visit , BMI measurement 19 kg/m2 27 kg/m2 Screening vist , 90 mmHg ≤ SBP ≤ 140 mmHg , 50 mmHg ≤ DBP ≤ 90 mmHg Fully understand purpose trial , test drug follow instruction trial , Those voluntarily write consent ability decision participate entire period test Those clinically significant history character ; Liver , kidney , digestive , respiratory , musculoskeletal , endocrine , neuropsychiatric , blood • tumor type , cardiovascular disease Those Gastrointestinal disease may affect absorption IND history surgery Those clinically significant history hypersensitivity drug food Those genetic problem , galactose intolerance , lactase deficiency glucosegalactose malabsorption Within 60 day take clinical trial drug Within 30 day take drug metabolizing enzyme induction inhibition drug prescription drug Within 30 day take food abnormally , may affect ADME drug Within 60 day donate whole blood , within 30 day donate blood partially , receive transfusion Within 14 day take OTC drug Those show positive drug abuse concern urine drug test Those drink excessive alcohol history alcoholism Heavy smoker</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>